Pemphigus Vulgaris Market Research Report - Global Forecast till 2027

Global Pemphigus Vulgaris Market: Information by Treatment (Corticosteroids, Immunosuppressants, Biological Therapies and Intravenous Immunoglobulin (IVIG) Therapy), by Route of Administration (Oral, Subcutaneous and Intravenous), by End User (Hospitals & Clinics, Specialty Dermatology Clinics and Research & Academic Laboratories), by Region (Americas, Europe, Asia-Pacific, Middle East & Africa) - Forecast till 2027

ID: MRFR/Pharma/5405-CR | July 2019 | Region: Global | 157 pages

Please note that the assessment period of report has been updated from 2018-2027 to 2020-2027. Cordially fill the sample form for updated data.

Pemphigus Vulgaris is a type of autoimmune disease in which the antibodies produced against the bacteria attack the healthy cells and causes skin problems. Pemphigus Vulgaris affects both men and women, but middle- and old-aged people are more likely to develop this condition.


Market Dynamics


The key factors responsible for influencing the market growth are the increasing prevalence of pemphigus vulgaris, rising bacterial and viral infection, and the growing prevalence of cancer. The side effects associated with the medication and increase in geriatric population are also estimated to drive the market during the forecast period. However, factors such as high cost related to treatment, unfavorable reimbursement situation, and lack of awareness are expected to restrain the market growth


Pemphigus vulgaris is one of the most life-threatening autoimmune skin disorders that occurs due to various reasons such as bacterial infection, increasing pollution, and side effects of some medications. According to the National Organization for Rare Disorders (NORD), 2015, the prevalence of pemphigus was high within the US and Europe affecting approximately 0.7 to 5 people per 1,000,000 each year in the overall population. It was also mentioned that pemphigus foliaceus a form of pemphigus vulgaris has a high prevalence in Africa and some rural areas in the world.


According to the International Pemphigus & Pemphigoid Foundation, it was predicted that approximately 40,000 to 50,000 people across the world and 2,500 people in the US were diagnosed with pemphigus disorder in 2017. The increase in the prevalence of pemphigus vulgaris across the globe is expected to drive market growth during the forecast period from 2018 to 2027.


Global Pemphigus Vulgaris Market Share, by Type, 2017 (%)  Pemphigus Vulgaris Market


Source: MRFR Analysis


Segmentation


The global pemphigus vulgaris market, by treatment, has been segmented into corticosteroids, immunosuppressants, biological therapies, and intravenous immunoglobulin (IVIG) therapy. Based on the route of administration, the market has been classified as intravenous, subcutaneous, and oral. By end user, the global pemphigus vulgaris market has been categorized as hospitals & clinics, specialty dermatology clinics, and research & academic laboratories.


Global Pemphigus Vulgaris Market Share, by Region, 2017 (%)  Pemphigus Vulgaris Market


Source: MRFR Analysis


Regional Analysis


The global pemphigus vulgaris market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.


The Americas accounted for the largest market share in 2017 and is estimated to dominate the global pemphigus vulgaris market. The Americas is anticipated to reach USD 2971.41 million by 2027 at a CAGR of 8.1% from 2018 to 2027. The Americas accounts for the largest regional market owing to the increasing prevalence of pemphigus vulgaris, increasing geriatric population, and raising funding for the research & development of skin diseases. According to the National Center for Biotechnology Information 2014, it was predicted that the prevalence of pemphigus vulgaris in the US is in the range of 0.76 to 5 new cases per million every year. Also, according to the International Pemphigus & Pemphigoid Foundation, it was projected that approximately 2,500 people in the US suffered from pemphigus disorder in 2017.


Europe accounted for the second-largest market share in 2017 due to extensive R&D for pemphigus vulgaris, increasing funding, and growing adoption of the technology within the region. Asia-Pacific is expected to contribute to the market growth for pemphigus vulgaris during the forecast period owing to rising therapeutic demand for pemphigus vulgaris and rapidly evolving healthcare sector. On the other hand, the Middle East & Africa is expected to observe slow growth due to low per capita disposable incomes, lack of awareness, and less exposure to healthcare services in this region.


Key Players


The prominent players in the global pemphigus vulgaris market are Almirall, SA, Argenx SE, Biogen Inc., F. Hoffmann-La Roche, Syntimmune, Pfizer Inc., Novartis AG, Sanofi, Janssen Global Services, LLC, and Principia Biopharma.


Some of the key strategies followed by players operating in the global pemphigus vulgaris market were innovation, product development, and acquisition & mergers.



  • In December 2017, Almirall SA and Athenex entered into a strategic partnership to develop and commercialize KX2-391 in the US and Europe for the treatment of actinic keratosis.



  • In January 2018, Pandion Therapeutics, a start-up led by former executives at Pfizer and Biogen, attracted USD 58 million in financing for the development of a new class of drugs that could tweak the immune system without triggering significant side effects.



  • In February 2018, Roche announced that the US Food and Drug Administration (FDA) had accepted the company’s supplemental biologics license application (SBLA) and granted priority review for the use of MabThera/Rituxan (Rituximab) for the treatment of pemphigus vulgaris (PV), a rare, life-threatening condition characterized by progressive painful blistering of the skin and mucous membranes.


Market Segmentation


Global Pemphigus Vulgaris Market, by Treatment



  • Corticosteroids

  • Immunosuppressants

  • Biological Therapies

  • Intravenous Immunoglobulin (IVIG) Therapy


Global Pemphigus Vulgaris Market, by Route of Administration



  • Intravenous

  • Subcutaneous

  • Oral


Global Pemphigus Vulgaris Market, by End User



  • Hospitals & Clinics

  • Specialty Dermatology Clinics

  • Research & Academic Laboratories


Global Pemphigus Vulgaris Market, by Region



  • Americas

    • North America

    • US

    • Canada





  • Europe

    • Western America

      • Germany

      • France

      • UK

      • Italy

      • Spain

      • Rest of Western Europe



    • Eastern Europe





  • Asia-Pacific

    • China

    • Japan

    • Australia

    • Republic of Korea

    • India

    • Rest of Asia-Pacific





  • Rest of the world


Available Additional Customizations



  • Treatment cost analysis

  • Epidemiology data

  • Clinical trials data


Intended Audience



  • Clinical laboratories

  • Pharmaceutical market

  • Government organizations

  • Research & consulting firms

  • Biotechnology companies



Frequently Asked Questions (FAQ) :


Pemphigus vulgaris market projected to grow at approximately 8% CAGR during the assessment period (2018-2027).

The valuation of the global pemphigus vulgaris market is estimated to increase to USD 677.99 MN by the end of 2027.

Rising prevalence and higher awareness regarding the disease and advancements in diagnosis & treatment process are major tailwinds pushing the growth of the global pemphigus vulgaris market.

North America holds the largest share in the global pemphigus vulgaris market, followed by Europe and the Asia Pacific, respectively.

Janssen Global Services LLC (U.S.), Syntimmune (India), Argenx SE (Belgium), Novartis AG (Switzerland), Sanofi (France), Pfizer Inc. (U.S.), Biogen Inc. (U.S.), Almirall SA (Spain), Principia Biopharma (U.S.), and F. Hoffman-La Roche (Switzerland), are some of the top players operating in the global pemphigus vulgaris market.

Pemphigus Vulgaris Market - Summary


Market Overview


Pemphigus vulgaris is a type of autoimmune disease, and the most common among the pemphigus group diseases. Autoimmune diseases occur when the body’s defense system mistakes organic, naturally occurring substances for foreign bodies and attacks them. This can cause widespread reaction within the body. Autoimmune diseases can be deadly for this reason. Until the discovery of immunosuppressants and corticosteroids, many autoimmune diseases had a much higher rate of mortality than at present.


Pemphigus vulgaris is the most common type of pemphigus disease in the United States and has an incidence of 0.5-3.2 per 100,000 worldwide. It results in painful lesions on the mucous membranes of the body, which exist in the mouth, nose, throat, eyes, lungs, and genitals. Pemphigus vulgaris lesions can also spread to join up with each other, creating much larger lesions that spread across the whole face and make it difficult and painful to swallow.


The pemphigus vulgaris market has grown rapidly in the last few decades, following the discovery of the effectiveness of corticosteroids and immunosuppressants in curbing the disease. Before this discovery, in the 1950s, pemphigus vulgaris had a death rate of almost 75%. The introduction of modern medication and early diagnostic procedures has also had a major impact on the mortality of the disease, thus driving the global pemphigus vulgaris market.


On the other hand, the potential hazards of pemphigus vulgaris medication can be a major restraint against the global pemphigus vulgaris market. While corticosteroids and immunosuppressants are powerful medications that are highly effective in treating pemphigus vulgaris, they are also highly bioactive compounds that can have other effects in the body. This is likely to be a major restraint against the global pemphigus vulgaris market and developing effective medication which does not affect the immune system is likely to be a key research channel for players in the global pemphigus vulgaris market over the forecast period.


Segmentation


The global pemphigus vulgaris market is segmented on the basis of treatment, route of administration, end use, and region. By treatment type, the pemphigus vulgaris market is segmented into corticosteroids, immunosuppressants, biological therapies, and intravenous immunoglobulin. Immunosuppressants hold the dominant share in the global pemphigus vulgaris market and are likely to remain the major treatment type over the forecast period due to their high effectiveness. By route of administration, the pemphigus vulgaris market is segmented into intravenous, subcutaneous, and oral. Intravenous administration is the most popular route of administration of pemphigus vulgaris drugs, followed by subcutaneous administration. By end-use, the market is segmented into hospitals and clinics, specialty dermatology clinics, and research and academic laboratories. By region, the pemphigus vulgaris market is segmented into the Americas, Europe, Asia Pacific, and rest of the world. The Americas and Europe hold dominant shares in the global pemphigus vulgaris market and are likely to remain the leading contributors to the global market over the forecast period due to the highly advanced state of the healthcare sector and the high prevalence of pemphigus vulgaris among people of Mediterranean descent.


Competitive Analysis


Leading players in the global pemphigus vulgaris market include Biogen Inc. (U.S.), Novartis AG (Switzerland), F. Hoffman-La Roche (Switzerland), Sanofi (France), Syntimmune (India), Argenx SE (Belgium), Janssen Global Services LLC (U.S.), Pfizer Inc. (U.S.), Almirall SA (Spain), and Principia Biopharma (U.S.).

1 Report Prologue

2 Market Introduction

2.1 Scope of Study 15

2.2 Research Objective 15

2.3 List of Assumptions 15

3 Research Methodology

3.1 Research Process 18

3.2 Primary Research 18

3.3 Secondary Research 19

3.4 Market Size Estimation 21

4 Market Dynamics

4.1 Introduction 23

4.2 Drivers 23

4.2.1 Increasing Prevalence of Pemphigus Vulgaris Globally 23

4.2.2 Growing Financial Support by Various Private and Government Organizations for Research of Diseases 23

4.2.3 Increasing Geriatric Population 23

4.3 Restraints 24

4.3.1 Lack of Awareness Among the Countries 24

4.3.2 High Cost of Treatment 24

4.4 Opportunities 24

4.4.1 Advancements in Treatments 24

4.5 Challenge 24

4.5.1 Adverse Side–Effects of the Treatment 24

5 Market Factor Analysis

5.1 Overview 26

5.1.1 R&D 26

5.1.2 Manufacturing 26

5.1.3 Distribution & Sales 26

5.1.4 Post–Sales Monitoring 27

5.2 Porter’s Five Forces Model 27

5.2.1 Overview 27

5.2.2 Bargaining Power of Suppliers 28

5.2.3 Bargaining Power of Buyers 28

5.2.4 Threat of New Entrants 28

5.3 Threat of Substitutes 28

5.4 Intensity of Rivalry 28

5.5 Investment Opportunity Analysis 29

6 Global Pemphigus Vulgaris Market, By Treatment

6.1 Introduction 31

6.2 Corticosteroids 33

6.3 Immunosuppressants 33

6.4 Biological Therapies 34

6.5 Intravenous Immunoglobulin (IVIG) Therapy 34

7 Global Pemphigus Vulgaris Market, By Route of Administration

7.1 Introduction 36

7.2 Intravenous 38

7.3 Subcutaneous 38

7.4 Oral 38

8 Global Pemphigus Vulgaris Market, By End–user

8.1 Introduction 40

8.2 Hospitals & Clinics 41

8.3 Specialty Dermatology Clinics 41

8.4 Research & Academic Laboratories 41

9 Global Pemphigus Vulgaris Market, By Region

9.1 Introduction 44

9.2 Americas 46

9.2.1 North America 48

9.2.1.1 US 50

9.2.1.2 Canada 51

9.2.2 South America 52

9.3 Europe 53

9.3.1 Western Europe 55

9.3.1.1 Germany 57

9.3.1.2 UK 58

9.3.1.3 France 59

9.3.1.4 Italy 60

9.3.1.5 Spain 61

9.3.1.6 Rest of Western Europe 62

9.3.2 Eastern Europe 63

9.4 Asia–Pacific 64

9.4.1 Japan 66

9.4.2 China 67

9.4.3 India 68

9.4.4 Australia 69

9.4.5 Republic of Korea 70

9.4.6 Rest of Asia–Pacific 71

9.5 Rest of the World 72

10 Competitive Landscape

10.1 Introduction 74

11 Company Profiles

11.1 Almirall, SA 76

11.1.1 Company Overview 76

11.1.2 Financial Overview 76

11.1.3 Products/Services Offered 77

11.1.4 Key Developments 77

11.1.5 SWOT Analysis 77

11.1.6 Key Strategy 77

11.2 Argenx SE 78

11.2.1 Company Overview 78

11.2.2 Financial Overview 78

11.2.3 Products/Services Offered 78

11.2.4 Key Developments 78

11.2.5 SWOT Analysis 79

11.2.6 Key Strategy 79

11.3 Biogen Inc. 80

11.3.1 Company Overview 80

11.3.2 Financial Overview 80

11.3.3 Products/Services Offered 81

11.3.4 Key Developments 81

11.3.5 SWOT Analysis 81

11.3.6 Key Strategy 81

11.4 F. Hoffmann–La Roche 82

11.4.1 Company Overview 82

11.4.2 Financial Overview 82

11.4.3 Products/Services Offered 83

11.4.4 SWOT Analysis 83

11.4.5 Key Strategy 83

11.5 Syntimmune 84

11.5.1 Company Overview 84

11.5.2 Financial Overview 84

11.5.3 Products/Services Offered 85

11.5.4 Key Developments 85

11.5.5 SWOT Analysis 85

11.5.6 Key Strategy 85

11.6 Pfizer Inc. 86

11.6.1 Company Overview 86

11.6.2 Financial Overview 86

11.6.3 Products/Services Offered 87

11.6.4 Key Developments 87

11.6.5 SWOT Analysis 87

11.6.6 Key Strategy 87

11.7 Novartis AG 88

11.7.1 Company Overview 88

11.7.2 Financial Overview 88

11.7.3 Products/Services Offered 89

11.7.4 Key Developments 89

11.7.5 SWOT Analysis 89

11.7.6 Key Strategy 89

11.8 Sanofi 90

11.8.1 Company Overview 90

11.8.2 Financial Overview 90

11.8.3 Products/Services Offered 91

11.8.4 Key Developments 91

11.8.5 SWOT Analysis 91

11.8.6 Key Strategy 91

11.9 Janssen Global Services, LLC 92

11.9.1 Company Overview 92

11.9.2 Financial Overview 92

11.9.3 Products/Services Offered 93

11.9.4 Key Developments 93

11.9.5 SWOT Analysis 93

11.9.6 Key Strategy 93

11.10 Principia Biopharma 94

11.10.1 Company Overview 94

11.10.2 Financial Overview 94

11.10.3 Products/Services Offered 94

11.10.4 Key Developments 94

11.10.5 SWOT Analysis 94

11.10.6 Key Strategy 94

12 Appendix

12.1 Discussion Blue Print 96

13 List of Tables

TABLE 1 LIST OF ASSUMPTIONS 14

TABLE 2 PRIMARY INTERVIEWS 17

TABLE 3 GLOBAL PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 31

TABLE 4 GLOBAL PEMPHIGUS VULGARIS MARKET, FOR CORTICOSTEROIDS 2020–2027 (USD MILLION) 32

TABLE 5 GLOBAL PEMPHIGUS VULGARIS MARKET, FOR IMMUNOSUPPRESSANTS 2020–2027 (USD MILLION) 32

TABLE 6 GLOBAL PEMPHIGUS VULGARIS MARKET, FOR BIOLOGICAL THERAPIES 2020–2027 (USD MILLION) 33

TABLE 7 GLOBAL PEMPHIGUS VULGARIS MARKET, FOR INTRAVENOUS IMMUNOGLOBULIN (IVIG) THERAPY 2020–2027 (USD MILLION) 33

TABLE 8 GLOBAL PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 35

TABLE 9 GLOBAL PEMPHIGUS VULGARIS MARKET, FOR INTRAVENOUS 2020–2027 (USD MILLION) 36

TABLE 10 GLOBAL PEMPHIGUS VULGARIS MARKET, FOR SUBCUTANEOUS 2020–2027 (USD MILLION) 36

TABLE 11 GLOBAL PEMPHIGUS VULGARIS MARKET, FOR ORAL 2020–2027 (USD MILLION) 36

TABLE 12 GLOBAL PEMPHIGUS VULGARIS MARKET, BY END–USER 2020–2027 (USD MILLION) 38

TABLE 13 GLOBAL PEMPHIGUS VULGARIS MARKET, FOR HOSPITALS & CLINICS 2020–2027 (USD MILLION) 39

TABLE 14 GLOBAL PEMPHIGUS VULGARIS MARKET, FOR SPECIALTY DERMATOLOGY CLINICS 2020–2027 (USD MILLION) 39

TABLE 15 GLOBAL PEMPHIGUS VULGARIS MARKET, FOR RESEARCH & ACADEMIC LABORATORIES 2020–2027 (USD MILLION) 39

TABLE 16 GLOBAL PEMPHIGUS VULGARIS MARKET, BY REGION 2020–2027 (USD MILLION) 42

TABLE 17 AMERICAS: PEMPHIGUS VULGARIS MARKET, BY REGION 2020–2027 (USD MILLION) 43

TABLE 18 AMERICAS: PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 43

TABLE 19 AMERICAS: PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 44

TABLE 20 AMERICAS: PEMPHIGUS VULGARIS MARKET, BY END USER 2020–2027 (USD MILLION) 44

TABLE 21 NORTH AMERICA: PEMPHIGUS VULGARIS MARKET, BY COUNTRY 2020–2027 (USD MILLION) 45

TABLE 22 NORTH AMERICA: PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 46

TABLE 23 NORTH AMERICA: PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 46

TABLE 24 NORTH AMERICA: PEMPHIGUS VULGARIS MARKET, BY END USER 2020–2027 (USD MILLION) 46

TABLE 25 US: PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 47

TABLE 26 US: PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 47

TABLE 27 US: PEMPHIGUS VULGARIS MARKET, BY END USER 2020–2027 (USD MILLION) 47

TABLE 28 CANADA: PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 48

TABLE 29 CANADA: PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 48

TABLE 30 CANADA: PEMPHIGUS VULGARIS MARKET, BY END USER 2020–2027 (USD MILLION) 48

TABLE 31 SOUTH AMERICA: PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 49

TABLE 32 SOUTH AMERICA: PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 49

TABLE 33 SOUTH AMERICA: PEMPHIGUS VULGARIS MARKET, BY END USER 2020–2027 (USD MILLION) 49

TABLE 34 EUROPE: PEMPHIGUS VULGARIS MARKET, BY REGION 2020–2027 (USD MILLION) 50

TABLE 35 EUROPE: PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 51

TABLE 36 EUROPE: PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 51

TABLE 37 EUROPE: PEMPHIGUS VULGARIS MARKET, BY END USER 2020–2027 (USD MILLION) 51

TABLE 38 WESTERN EUROPE: PEMPHIGUS VULGARIS MARKET, BY COUNTRY 2020–2027 (USD MILLION) 52

TABLE 39 WESTERN EUROPE: PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 53

TABLE 40 WESTERN EUROPE: PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 53

TABLE 41 WESTERN EUROPE: PEMPHIGUS VULGARIS MARKET, BY END USER 2020–2027 (USD MILLION) 53

TABLE 42 GERMANY: PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 54

TABLE 43 GERMANY: PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 54

TABLE 44 GERMANY: PEMPHIGUS VULGARIS MARKET, BY END USER 2020–2027 (USD MILLION) 54

TABLE 45 UK: PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 55

TABLE 46 UK: PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 55

TABLE 47 UK: PEMPHIGUS VULGARIS MARKET, BY END USER 2020–2027 (USD MILLION) 55

TABLE 48 FRANCE: PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 56

TABLE 49 FRANCE: PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 56

TABLE 50 FRANCE: PEMPHIGUS VULGARIS MARKET, BY END USER 2020–2027 (USD MILLION) 56

TABLE 51 ITALY: PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 57

TABLE 52 ITALY: PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 57

TABLE 53 ITALY: PEMPHIGUS VULGARIS MARKET, BY END USER 2020–2027 (USD MILLION) 57

TABLE 54 SPAIN: PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 58

TABLE 55 SPAIN: PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 58

TABLE 56 SPAIN: PEMPHIGUS VULGARIS MARKET, BY END USER 2020–2027 (USD MILLION) 58

TABLE 57 REST OF WESTERN EUROPE: PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 59

TABLE 58 REST OF WESTERN EUROPE: PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 59

TABLE 59 REST OF WESTERN EUROPE: PEMPHIGUS VULGARIS MARKET, BY END USER 2020–2027 (USD MILLION) 59

TABLE 60 EASTERN EUROPE: PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 60

TABLE 61 EASTERN EUROPE: PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 60

TABLE 62 EASTERN EUROPE: PEMPHIGUS VULGARIS MARKET, BY END USER 2020–2027 (USD MILLION) 60

TABLE 63 ASIA-PACIFIC: PEMPHIGUS VULGARIS MARKET, BY COUNTRY/REGION 2020–2027 (USD MILLION) 61

TABLE 64 ASIA-PACIFIC: PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 62

TABLE 65 ASIA-PACIFIC: PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 62

TABLE 66 ASIA-PACIFIC: PEMPHIGUS VULGARIS MARKET, BY END USER 2020–2027 (USD MILLION) 62

TABLE 67 JAPAN: PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 63

TABLE 68 JAPAN: PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 63

TABLE 69 JAPAN: PEMPHIGUS VULGARIS MARKET, BY END USER 2020–2027 (USD MILLION) 63

TABLE 70 CHINA: PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 64

TABLE 71 CHINA: PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 64

TABLE 72 CHINA: PEMPHIGUS VULGARIS MARKET, BY END USER 2020–2027 (USD MILLION) 64

TABLE 73 INDIA: PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 65

TABLE 74 INDIA: PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 65

TABLE 75 INDIA: PEMPHIGUS VULGARIS MARKET, BY END USER 2020–2027 (USD MILLION) 65

TABLE 76 AUSTRALIA: PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 66

TABLE 77 AUSTRALIA: PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 66

TABLE 78 AUSTRALIA: PEMPHIGUS VULGARIS MARKET, BY END USER 2020–2027 (USD MILLION) 66

TABLE 79 REPUBLIC OF KOREA: PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 67

TABLE 80 REPUBLIC OF KOREA: PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 67

TABLE 81 REPUBLIC OF KOREA: PEMPHIGUS VULGARIS MARKET, BY END USER 2020–2027 (USD MILLION) 67

TABLE 82 REST OF ASIA-PACIFIC: PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 68

TABLE 83 REST OF ASIA-PACIFIC: PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 68

TABLE 84 REST OF ASIA-PACIFIC: PEMPHIGUS VULGARIS MARKET, BY END USER 2020–2027 (USD MILLION) 68

TABLE 85 REST OF THE WORLD: PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2020–2027 (USD MILLION) 69

TABLE 86 REST OF THE WORLD: PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2020–2027 (USD MILLION) 69

TABLE 87 REST OF THE WORLD: PEMPHIGUS VULGARIS MARKET, BY END USER 2020–2027 (USD MILLION) 69

14 List of Figures

FIGURE 1 GLOBAL PEMPHIGUS VULGARIS MARKET: MARKET STRUCTURE 15

FIGURE 2 RESEARCH PROCESS 17

FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH 20

FIGURE 4 SUPPLY CHAIN: GLOBAL PEMPHIGUS VULGARIS MARKET 25

FIGURE 5 PORTER’S FIVE FORCES ANALYSIS: GLOBAL PEMPHIGUS VULGARIS MARKET 26

FIGURE 6 GLOBAL PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2020 & 2027 (USD MILLION) 31

FIGURE 7 GLOBAL PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2020 & 2027 (USD MILLION) 35

FIGURE 8 GLOBAL PEMPHIGUS VULGARIS MARKET, BY END-USER 2020 & 2027 (USD MILLION) 38

FIGURE 9 GLOBAL PEMPHIGUS VULGARIS MARKET SHARE, BY REGION 2020 (%) 42

FIGURE 10 AMERICAS: PEMPHIGUS VULGARIS MARKET SHARE, BY REGION 2020 (%) 43

FIGURE 11 NORTH AMERICA: PEMPHIGUS VULGARIS MARKET SAHRE, BY COUNTRY 2020 (%) 45

FIGURE 12 EUROPE: PEMPHIGUS VULGARIS MARKET SHARE, BY REGION 2020 (%) 50

FIGURE 13 WESTERN EUROPE: PEMPHIGUS VULGARIS MARKET SAHRE, BY CONTRY 2020 (%) 52

FIGURE 14 ASIA-PACIFIC: PEMPHIGUS VULGARIS MARKET, BY COUNTRY/REGION 2020 (%) 61

FIGURE 15 TOP PLAYERS IN THE GLOBAL PEMPHIGUS VULGARIS MARKET 71

Global Pemphigus Vulgaris Market: Competitive Landscape


The Global Pemphigus Vulgaris Market is characterized by the presence of many global, regional, and local vendors. There are many large and small players are operating in the global pemphigus vulgaris market. The market is highly competitive with all the players competing to gain market share. Rising competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth. The manufacturers compete based on cost, quality, and reliability. It is decisive for the manufacturers to provide cost-efficient and high-quality products, to survive and succeed in an intensely competitive market environment. Some of the top players in this market are F. Hoffmann-La Roche, Argenx SE, Pfizer Inc., and Novartis AG which holds the significant market share.


Hoffmann-La Roche a Swiss multinational healthcare company headquartered in Switzerland. The company is involved in producing differentiated solutions for oncology, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. The company also provides innovative diagnostic tests and medicines which will help patients around the world. In February 2018, F. Hoffmann-La Roche announced that the US Food and Drug Administration (FDA) has accepted the company’s Supplemental Biologics License Application (sBLA) and granted priority review for the use of MabThera/Rituxan (Rituximab) for the treatment of pemphigus vulgaris (PV), a rare, life-threatening condition characterized by progressive painful blistering of the skin and mucous membranes.


Argenx SE is a Zwijnaarde based company. It is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. The company focuses on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets to treat diseases with significant unmet medical needs. In March 2018, the company announced the expansion of its pipeline with the addition of complement-targeted ARGX-117 for the treatment of severe autoimmune diseases.


Pfizer Inc. is one of the top pharmaceutical company headquartered in the US. The company is involved in developing wide range of medical disciplines that include immunology, oncology, cardiology, diabetology/endocrinology, and neurology. Pfizer operates in countries such as Germany, France, Greece, Korea, Mexico, Russia, the Netherlands, India, Poland, Turkey, Israel, China, and others. In December 2016 the company received the US Food and Drug Administration (FDA) approval for EUCRISATM (crisaborole) ointment applicable for the treatment of atopic dermatitis (AD). EUCRISATM (crisaborole) is a non-steroid ointment that prevents the Phosphodiesterase -4 enzyme in the skin.


Novartis AG holds a strong position in pharmaceutical industry. The company is engaged in new product launches and strategic acquisitions to rise there its market presence. In January 2018, the company receives the US FDA approval for Promacta (eltrombopag) which is used for the treatment of severe aplastic anemia (SAA) as a first-line therapy.


The growth of pemphigus vulgaris market is dependent on the market conditions, government support, and industry development. Thus, the companies are focusing on expanding geographically, collaborations, product launches, mergers and acquisitions and improving their products.


Intended Audience:



  • Pharmaceutical Companies

  • Biotech Companies

  • Governmental and Private Laboratories

  • Research Institutes and Academic Centers

  • Market Research and Consulting

  • End-User Sectors